Clinical Trials

A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy

Study ID
Bristol-Myers Squibb CA209-040

NCT Number
NCT01658878 (Click on the NCT number for more information about the trial)

Research Study Number

Principle Investigator
Dr. Martin Gutierrez


Bristol-Myers Squibb

Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at

Apply Now